The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.
|Articles|February 15, 2004
Data on obesity-PCa link mount, but conflict
Las Vegas--Obesity in prostate cancer patients is associated withhigher-grade tumors, cancer recurrence, and more aggressive disease, recentstudies have shown. The research has prompted some urologists to suggestusing body mass index (BMI) as a marker for early screening and treatment.Others suggest that further studies should be undertaken to determine ifweight loss may, in fact, lower prostate cancer risk.
Advertisement
Advertisement
Related to this article
At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
Adding perioperative pembrolizumab to chemotherapy does not improve EFS in MIBC
3
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5